Key facts
- Spore.Bio’s last known valuation is $60.6M (Feb 2025).
- It has raised $31.7M; the latest was Early Stage VC ($22.9M) in Jan 2026.
- Notable investors include Plug and Play Tech Center, Kima Ventures, Entrepreneurs First, La French Tech, Phoenix Court — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Spore.Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Spore.Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Spore.Bio
Developer of a bacterial detection technology designed to develop technological tools to help the food and beverage industry. The company offers a new generation of microbiological technologies directly usable on the shop floor, combining cutting-edge optical technology with advanced machine-learning models, enabling cosmetics and pharmaceutical factories to help factories manufacture safe products.
- Sector
- Business Products and Services (B2B)
- HQ
- Paris, France
- Founded
- 2022
- Employees
- 50
- Website
- spore.bio/
- Ownership
- Privately Held (backing)
Spore.Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spore.Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spore.Bio in its N-PORT filings yet. We sweep new filings monthly.